About Saya Bio
Saya Bio is a venture capital firm founded in 2020. It is primarily based out of Madrid, Spain. As of Sep 2021, Saya Bio has invested in 17 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Series A round of Delix Therapeutics Overall, Saya Bio portfolio has seen 1 unicorn, 1 IPO and 1 acquisition, namely Virta, Alto and atai Life Sciences. A lot of funds co-invest with Saya Bio, with names like Artis Ventures sharing a substantial percentage of its portfolio. Saya Bio has team of 7 people including 2 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Portfolio Soonicorns
Saya Bio's List of Top Investments
Saya Bio has a portfolio of 17 companies, one of which is a Unicorn. Their most notable investments include Virta and Alto.Their portfolio spans across United States, Germany, Netherlands and 1 more locations. They have invested in Life Sciences, HealthTech, High Tech and 6 other sectors, across stages such as Series A stage. Here is the list of top investments by Saya Bio:
1. Virta
Virta Health develops and delivers clinically proven and individualized therapies to restore metabolic health in chronic disease patients. The clinically proven therapies are possible by combining advanced biochemistry, clinical expertise, data science, and digital tools. The also provides therapies for treating diabetes.
Key facts about Virta
- Founded Year: 2014
- Location: San Francisco (United States)
- Valuation: $*****
- Stage: Series E
- Total Funding till date: $402M
- Employee Count: 879 as on Mar 31, 2026
- Investors: Allen & Company, Creandum and 28 Others
- Latest Funding Round: Series E, Apr 19, 2021, $*****
- Highlight: Editors' Pick
_1584015723684.png?format=webp&height=120&width=120){kind=logo}
2. Alto
Online pharmacy offering prescription delivery services. The platform enables users to find and compare prices of medications and can receive over-the-counter and generic medicines at home. It also, offers platform for pharmacists for prescription management.
Key facts about Alto
- Founded Year: 2015
- Location: San Francisco (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $592M
- Employee Count: 824 as on Mar 31, 2026
- Investors: Meritech, Spur Capital and 35 Others
- Latest Funding Round: Series E, Jan 14, 2022, $*****
- Highlight: Acquired
3. Truvian
Developer of automated benchtop blood testing system for labs. The company has developed a patented diagnostic platform, that enables comprehensive blood testing using chemistries, immunoassays, and hematology assays using a small sample of blood.
Key facts about Truvian
- Founded Year: 2015
- Location: San Diego (United States)
- Stage: Series C
- Total Funding till date: $208M
- Employee Count: 113 as on Mar 31, 2026
- Investors: Domain Associates, Spring Creek Partners and 21 Others
- Latest Funding Round: Series C, Jul 17, 2024, $*****
- Highlight: Editors' Pick
Tessera Therapeutics is a provider of new genome engineering technology for treating multiple diseases. It offers a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. It offers RNA gene writings that can change base pairs, make small insertions or deletions, and integrate entire genes into the genome.
Key facts about Tessera Therapeutics
- Founded Year: 2017
- Location: Cambridge (United States)
- Stage: Series C
- Total Funding till date: $610M
- Employee Count: 225 as on Mar 31, 2026
- Investors: ADIA, Temasek and 22 Others
- Latest Funding Round: Series C, Apr 19, 2022, $*****
- Highlight: Editors' Pick
Developer of therapeutic solutions for the treatment of multiple neurological disorders. The company is involved in the development of small molecule-based, non-hallucinogenic versions of psychedelic compounds that enabling healthcare service providers to cure patients suffering from depression, anxiety, and post-traumatic stress disorders.
Key facts about Delix Therapeutics
- Founded Year: 2019
- Location: Menlo Park (United States)
- Stage: Series A
- Total Funding till date: $100M
- Employee Count: 26 as on Mar 31, 2026
- Investors: RA Capital Management, Comerica and 22 Others
- Latest Funding Round: Grant (prize money), Jun 04, 2024, $*****
- Highlight: Editors' Pick
Saya Bio's Year-on-Year Investment Trends
Saya Bio has invested in 17 companies over the last 5 years, with an average of 0 new investment annually in the last 5 years. Its most recent first time investment was in Delix Therapeutics.Saya Bio's Investments by Stage
Saya Bio has made 1 investment in Series A stage with an average round size of $70M.Saya Bio's Investments by Sector
Saya Bio has a diverse portfolio, with companies operating in the Consumer and Life Sciences. Notably, it has invested in 14 Tech companies, 11 Enterprise (B2B) companies, 4 Consumer (B2C) companies and at least 3 companies focusing on Software.Saya Bio's Investments by Geography
Saya Bio has made most investments in United States (1).Saya Bio's recent investments
Saya Bio has not made any investment in 2026 so far.Here are the most recent investments by Saya Bio:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 27, 2021 | United States | Series A | 8985 | [+16] |
Unicorns in Saya Bio's Portfolio
Saya Bio has 1 unicorn in its portfolio - Virta. The most recent unicorn in their portfolio is Virta which became a unicorn in 2021, 5 years before Saya Bio first invested in it.Here is a list of unicorns in Saya Bio's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
77 | Provider of therapies for metabolic health in chronic disease patients | 2014 | San Francisco | Series E | dzznvqb |
IPOs and Publicly Listed companies in Saya Bio's Portfolio
1 of Saya Bio's portfolio company became public - atai Life Sciences. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jun 2021 at marketcap of $2.29BHere are Saya Bio's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 18, 2021 | - | - | 4495 |
Acquired companies in Saya Bio's Portfolio
1 company from Saya Bio's portfolio has been acquired. The most recent acquisition was Alto in Mar 2025 by Fuze Health for $*****.Here are Saya Bio's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 21, 2025 | - | - | 4109 |
_1584015723684.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Team profile of Saya Bio
Saya Bio has a team of 7 members including 2 Partners. Saya Bio's team does not sit on the board of any company as of now.Co-investors of Saya Bio
Over the past 5 years, 20 investors have co-invested in Saya Bio's portfolio companies. This includes funds and angels.
- Top Co-investors of Saya Bio: 17 investors entered a company along with Saya Bio. These include investors like Artis Ventures (1 company).
- Invested after Saya Bio: A total of 3 investors have invested in Saya Bio's portfolio after their investments. Top Investors include Defense.gov (1 company), Comerica (1 company) and HHS (1 company).
Recent News related to Saya Bio
•
Saya Biologics Partners with Enzene to Develop and Manufacture Two Osteoporosis Therapies for Mexicopharmasource.global•Dec 08, 2025•Enzene, Saya Bio
•
Delix Therapeutics Raises $70 MillionGreen Market Report•Sep 27, 2021•Delix Therapeutics, Artis Ventures, RA Capital Management, Apeiron and 14 others
